Sagittarius Life Science Corp.

Sagittarius Life Science Corp.

TTPEX:3205
42.50
TWD
-0.35
(-0.82%)
-0.25EPS
3.52BMarket Cap

Total Valuation

TWD

As of June 30, 2026, Sagittarius Life Science Corp. carries a market capitalization of 3.52B, placing it among publicly traded companies globally. Its enterprise value stands at 2.96B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap3.52B
Enterprise Value2.96B

Share Statistics

As of June 30, 2026, Sagittarius Life Science Corp. has 67.55M shares outstanding.

Shares Outstanding67.55M

Valuation Ratios

These figures are as of June 30, 2026. The price-to-sales ratio is 7.91, and the price-to-book ratio stands at 3.52.

PS Ratio7.91
PB Ratio3.52
P/TBV Ratio3.52
P/FCF Ratio-14.16
P/OCF Ratio-17.59

Enterprise Valuation

These figures are as of June 30, 2026. The EV/Sales ratio of 6.33 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 2.96B versus a market cap of 3.52B, with the gap driven by net debt and cash on the balance sheet.

EV / Sales6.33

Financial Position

As of June 30, 2026, Sagittarius Life Science Corp. maintains a current ratio of 6.62, meaning it holds 6.6x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 7.34, indicating elevated leverage, while an interest coverage ratio of -97.51 demonstrates limited ability to service its debt obligations.

Current Ratio6.62
Quick Ratio4.77
Debt / Equity7.34
Debt / EBITDA-2.89
Interest Coverage-97.51

Financial Efficiency

TWD

Over the twelve months ended June 30, 2026, Sagittarius Life Science Corp. posted a negative return on equity (ROE) of -1.60, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -1.44, reflecting losses generated across the asset base. The company generates approximately 5.57M in revenue per employee across its workforce of 84.00, a quick read on workforce productivity versus industry peers. Inventory turnover of 8.18 indicates how many times Sagittarius Life Science Corp. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Return on Equity (ROE)-1.60
Return on Assets (ROA)-1.44
Revenue Per Employee5.57M
Employee Count84.00
Inventory Turnover8.18

Stock Price Statistics

TWD

As of the close on November 17, 2026, Sagittarius Life Science Corp.'s stock has declined approximately 7.21% over the past 52 weeks. The 50-day moving average sits at 46.07, while the 200-day moving average is 50.81.

52-Week Price Change-7.21%
50-Day Moving Average46.07
200-Day Moving Average50.81

Income Statement

TWD

Over the twelve months ended June 30, 2026, Sagittarius Life Science Corp. generated 467.69M in revenue and converted that into -16.46M in net income, yielding earnings per share of -0.25. EBITDA reached -25.45M, while operating income came in at -32.76M.

Revenue467.69M
Gross Profit42.12M
Operating Income-32.76M
Pretax Income-17.74M
Net Income-16.46M
EBITDA-25.45M
EBIT-32.76M
Earnings Per Share (EPS)-0.25

Balance Sheet

TWD

As of June 30, 2026, Sagittarius Life Science Corp. holds 635.12M in cash and equivalents against 73.60M in total debt, resulting in a net debt position of -82.20M. Total book value stands at 1.00B, with working capital of 748.84M providing operational flexibility.

Cash & Cash Equivalents635.12M
Total Debt73.60M
Net Debt-82.20M
Equity (Book Value)1.00B
Book Value Per Share14.82
Working Capital748.84M

Cash Flow

TWD

Sagittarius Life Science Corp. produced -210.21M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -50.95M in capital expenditures, free cash flow totaled -261.16M - equivalent to -3.68 per share.

Operating Cash Flow-210.21M
Capital Expenditures-50.95M
Free Cash Flow-261.16M
FCF Per Share-3.68

Margins

Over the twelve months ended June 30, 2026, Sagittarius Life Science Corp. posted a gross margin of 9.01, reflecting its pricing power and cost economics. The operating margin of -7.01 and net profit margin of -3.52 provide insight into operational efficiency.

Gross Margin9.01
Operating Margin-7.01
Pretax Margin-3.79
Profit Margin-3.52
EBITDA Margin-5.44

Dividends & Yields

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -7.06: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -1.88, meaning Sagittarius Life Science Corp. raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Shareholder Yield-1.88
FCF Yield-7.06

Stock Splits

Sagittarius Life Science Corp.'s most recent stock split took place on August 17, 2016 with a 328:347 split ratio.

Last Split Date8/17/2016
Split Ratio328:347

Scores

As of June 30, 2026, Sagittarius Life Science Corp. has an Altman Z-Score of 16.75, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score16.75